Discover Our Latest Resources

Accurate measurement of AAV vector genomes is the foundation of high-yield, high-quality gene therapy. Yet many workflows still rely on outdated tools which often lead to misleading titer estimates and suboptimal processes. Generating a suitable yield of high-quality recombinant AAV product starts with an effective analytical process.

Did you know that “true full” therapeutic vector genomes are often the minority in recombinant adeno-associated virus (rAAV) populations for gene therapy, perhaps more so than current analytical methods reveal?

Poster from UMass Chan Medical School for ASGCT 2025, demonstrating the efficiency of the nanoneedle assays to provide direct measure of capsids containing complete genomes.

Poster presented by our Team at ASGCT 2025, New Orleans.

A novel nanoneedle technology
for assessment of AAV product quality and manufacturing performance

Rewatch our GEN Webinar from May 2025

Nanomosaic Announced Release of Joint White Paper with BMS Investigating Nanoneedle Technology to Improve AAV Manufacturing Process and Product Quality.

Nanomosaic, the multiplex and multi-omic marker analysis company, today announced major technical and commercial milestones for its Tessie system and assays optimized for gene therapy applications, evidencing the need for improved analytics across development and manufacturing processes.

Successful gene therapy development manufacturing at scale is a matter of ensuring an optimal vector for the genetic material, as well as the integrity of this one, to guarantee the treatment effectiveness. In this Application Note, our team demonstrates how NanoMosaic’s platform allows researchers to obtain high throughputs and a high level of accuracy to characterize capsids and transgenes—all from a single instrument.

Did you miss the chance to book one of our Lunch and Learn sessions this August? No worries! You can still catch up on the "Learn" part!

NanoMosaic's team has developed Tessie, a benchtop reader designed to address the specific challenges of gene therapy manufacturing. Tessie supports the largest gene therapy throughputs, enabling your team to characterize transgenes and capsids using a single instrument and advanced data analysis capabilities.

In this webinar our speakers will introduce NanoMosaic’s Tessie™, a fit-for-purpose platform for gene therapy applications that effectively combines protein and nucleic acid quantification in a single run. During the webinar, they will discuss how Tessie detects and characterizes AAV capsids as well as full, empty, partial, and internally deleted transgenes directly from crude extracts.

WALTHAM, Mass. PRNewswire.